Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
